# Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

> **NCT02336646** · PHASE1 · COMPLETED · sponsor: **Taiwan Bio Therapeutics Inc.** · enrollment: 18 (actual)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **DRUG:** Allogenic MSC
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT02336646
- **Lead sponsor:** Taiwan Bio Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-01
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-12-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336646, "Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02336646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*